Clinical Trial Update: Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjunctive lisdexamfetamine for bipolar depression was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• Lisdexamfetamine (lisdexamfetamine dimesylate)

Snippet

Sponsor: Lindner Center of HOPE | Conditions: Bipolar, Depression | Phase 3 | Status: TERMINATED